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Abstract PTEN is one of the most frequently mutated
tumor suppressor genes in human cancers. Mutations occur
in either heritable or sporadic fashion. Sequencing of
cDNA from patients and normal individuals often reveals
splicing variants (SVs) of PTEN, some of which are non-
mutation related. To investigate whether these SVs were
the result of illegitimate splicing (a general decrease of
Wdelity in splicing site selection in “aged” samples), we
tested “aged” blood from individuals who had normal
PTEN transcripts in their “fresh” mononuclear cells. Blood
from 20 normal individuals was collected and split into two
aliquots. Total RNA and DNA were extracted immediately
(“fresh”) and 48 h later (“aged”), respectively. Using
RT-PCR, subcloning and sequencing, we found seven
types of SVs. No mutation was detected in the related
intron–exon  Xanking region in genomic DNA in either
“fresh” or “aged” samples. Some of the SVs were also con-
sistently present in both the “fresh” and “aged” EBV-trans-
formed lymphoblastoid cells from six normal individuals.
Western blot data indicated that the PTEN protein level (in
full length) was not altered in the “fresh” EBV-transformed
lymphoblastoid cells with SVs. In conclusion, our data
demonstrate that PTEN illegitimate splicing often occurs in
“aged” blood and EBV-transformed lymphoblastoid cells.
Therefore, it is critical to note the time point of RNA
extraction when investigating for PTEN aberrant tran-
scripts. We hope that our data will increase awareness
about the sample status, because gene expression data may
be potentially Xawed from “aged” samples, particularly
when dealing with clinical samples.
Introduction
PTEN (phosphatase and tensin homolog deleted on chro-
mosome ten)/MMAC1 (mutated in multiple advanced canc-
ers)/TEP1 (TGF--regulated and epithelial cell-enriched
phosphatase, referred hereafter as PTEN), as a tumor sup-
pressor, is a central negative regulator of the PI3K/AKT
signaling cascade that inXuences multiple cellular functions
including cell growth, survival, proliferation, and migration
in a context-dependent manner (Carracedo and PandolW
2008). Germline mutations of PTEN (DNA Accession#
AF067844, mRNA Accession# U92436, or U93051) cause
the inherited Cowden Syndrome (CS; MIM 158350) and
Bannayan–Riley–Ruvalcaba Syndrome (BRRS; MIM
153480) (Liaw et al. 1997; Marsh et al. 1998; Zhou et al.
2003). Somatic intragenic mutations or deletions of PTEN
have been found in a wide variety of advanced sporadic
tumors in humans, such as brain, breast, prostate, lung,
ovary, thyroid, melanoma, endometrial, acute leukemia,
and non-Hodgkin’s lymphoma (Dahia et al. 1997,  1999;
Kurose et al. 2001; Soria et al. 2002; Tashiro et al. 1997;
Wang et al. 1997; Zhou et al. 2003). We recently reported
that PTEN protein is also deWcient in juvenile myelomono-
cytic leukemia (JMML) (Liu et al. 2009). Data from pri-
mary human tumors, as well as animal models, support the
concept that the impact of PTEN inactivation is tissue-
speciWc. For many years, researchers have been struggling
to identify the mechanism that causes the deWciency in
PTEN function. Some studies have demonstrated intriguing
discontinuities between PTEN mutations and the subse-
quent phenotypes. Several groups have reported splice
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variants on PTEN in normal individuals (Sharrard and
Maitland 2000), patients with inherited diseases or cancer
(Agrawal and Eng 2006; Celebi et al. 2000), and tumor cell
lines (Sharrard and Maitland 2000). However, only a few of
them are mutation-associated (Celebi et al. 2000).
In the process of screening for PTEN mutations in
patients with JMML, we found several aberrantly spliced
transcripts, which were not related to any mutation at either
the splice-donor and receptor-site, nor branch site. Alterna-
tive splicing is an important mechanism to create protein
diversity and regulate gene expression in a tissue- and
developmental-speciWc manner, and it plays an important
role in cancer development (for more background see
reviews by Caceres and Kalnina) (Caceres and Kornblihtt
2002; Kalnina et al. 2005). Studying alternative splicing
has been very challenging due to the poor understanding of
the mechanism of splicing regulation and the complexity of
tissue status, which makes it very diYcult to interpret data.
In order to exclude that the SVs were not the result of ille-
gitimate splicing (deWned as a general decrease of Wdelity
in selection of splicing site in “aged” samples), a study was
conducted on peripheral blood and Epstein–Barr virus
(EBV)-transformed lymphoblastoid cells from normal indi-
viduals who did not have any aberrant splicing in mononu-
clear cells (MNCs) from their “fresh” blood samples.
Methods
Sample preparation
Blood from normal individuals was collected into heparin-
ized tubes and split into two aliquots. MNCs were isolated
immediately (“fresh”) from one aliquot following the pro-
cedure previously reported (Liu et al. 2009). The second
aliquot was kept at room temperature and the MNCs were
isolated after 48 h (“aged”). Permission to use samples of
normal individuals was granted by the Institutional Review
Boards (IRB) at the University of Alabama at Birmingham
and University of Arkansas for Medical Sciences.
EBV lymphoblastoid cell lines
Epstein–Barr virus-transformed lymphoblastoid cell lines
from healthy individuals were established following the
modiWed protocol by Glick (Glick 1980). BrieXy, infectious
EBV was obtained from 10-day-old cell-free supernatant of
the virus producer B95-8 cell line (ATCC, Manassas, VA).
MNCs from “fresh” blood were transformed in a density of
10 £ 106/ml in 2 ml of EBV virus supernatant for 3–6 h in
5% CO2 at 37°C, then the culture volume was expanded by
adding RPMI-1640 medium (containing 20% FBS plus
penicillin and streptomycin) and cyclosporine A (Sigma–
Aldrich, St. Louis, MO) in a Wnal concentration of 0.5 g/ml
to dilute the Wnal cell density to 1 £ 106/ml. The cultures
were then incubated in 5% CO2 at 37°C for 5–8 weeks until
the cells were transformed and proliferating (watched for
signs of gross clumping). Cells were frozen in 10% DMSO
in 100% FBS and stored in liquid nitrogen for future
analysis.
Extraction of DNA and RNA
Mononuclear cells were lysed in Trizol reagent® (Invitro-
gen, Carlsbad, CA) immediately after being isolated. In
order to prevent RNA degradation, EBV cell lines were
pre-treated with puromycin (150 g/ml) for 6 h before cell
lysis. Total RNA and DNA were extracted from cell lysates
according to the manufacturer’s instruction, and quantiWed
spectrophotometrically.
RNA integrity analysis
To determine the quality and quantity of RNA, one micro-
liter of sample was analyzed using the RNA 6000 Nano Chip
kit and the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Inc, Santa Clara, CA). Concentrations are determined
as nanogram per microliter and the integrity of the RNA is
scored with an RNA integrity number (RIN) that grades
RNA integrity from 0 (decayed) to 10 (intact).
RT-PCR and sequence analysis
Genomic DNA was removed from RNA by using the
DNA-free kit (Ambion®, Austin, TX) in order to prevent an
ampliWcation of the PTEN pseudogene. Two hundred
twenty nanograms of total RNA were used as templates to
synthesize Wrst strand cDNA, in a total volume of 100 l by
using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). The Wrst-run PCR
was ampliWed using GeneAmp PCR System 2700 (Perkin-
Elmer Corp., Branchbury, NJ) and Platinum® Taq DNA
polymerase high Wdelity kit (Invitrogen). A 50 l of total
volume of PCR reaction contained 1–5 l of template, 5 l
of 10£ high Wdelity PCR buVer, 2 mM MgSO2, 250 M of
each dNTPs, 1 unit Platinum® Taq DNA polymerase high
Wdelity, and 20 pmol of forward and reverse primers. PTEN
primer sequences are listed in Table 1. AmpliWcation
employed 35 cycles of the following sequence: denatur-
ation at 94°C for 10 s, annealing at 54–58°C for 30–60 s,
and elongation at 68°C for 90 s. Primers (1005F/2260R) for
the full length of PTEN-coding sequences were used in the
Wrst-run PCR. For sequencing, a pair of nested primers
(92436F/871R) was used. For SVs screening, a pair of
exon-speciWc primers was used in a second run PCR for
each exon and Xanking region (92436F/225R for intron-3Hum Genet (2010) 128:609–614 611
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insertion, 324F/501R for intron-5 insertion, 324F/647R for
exon-6 deletion). In order to ensure that there was no con-
tamination by genomic DNA of the PTEN pseudogene, the
same amount of total RNA (without being reverse-tran-
scribed) from randomly selected control samples was
ampliWed with the identical primers. AmpliWed PCR prod-
ucts were analyzed using electrophoresis with a 1.0–1.5%
agarose gel stained with 0.5 g/ml ethidium bromide. Prod-
ucts of nested PCR were ampliWed and puriWed by using
TA Cloning Kit (Invitrogen) following the manufacture’s
instruction. Plasmid DNAs were puriWed using a miniPrep
kit (Qiagen, Valencia, CA). Sequencing of puriWed prod-
ucts was performed using an ABI 373A DNA sequencer
(Applied Biosystems). The sequence was analyzed using
DNASIS-Mac v2.0 software.
Western blot
Unstimulated EBV lymphoblastoid cells from normal indi-
viduals were used for cell lysates. Western blots were per-
formed as previously reported (Liu et al. 2009). BrieXy,
25 g of cell lysate protein were separated in 10% SDS–
polyacrylamide gel (SDS–PAGE). Protein bands were elec-
tro-transferred onto a polyvinylidene diXuoride (PVDF)
membrane, and blocked in 5% BSA/TBST (20 mM Tris–
HCl, pH 7.6, 150 mM NaCl, 0.1% Tween-20) for 1 h in
room temperature. An antibody against human PTEN in
rabbit antiserum (Upstate, Lake Placid, NY) was hybrid-
ized with the membrane at a concentration of 1:1,000 in 5%
BSA-TBST overnight at 4°C. The protein bands were
detected by incubating the blot with 1:15,000 dilution of
horseradish peroxide-conjugated anti-rabbit immunoglobin
(Amersham Pharmacia biotech, Amersham Place, UK) for
1 h in room temperature, and then the blot was developed
with ECL plus (Amersham Pharmacia Biotech) according
to the manufacturer’s instructions. The densities of protein
bands were documented with Kodak XAR Wlms. The same
blot was further stripped with Restore™ Western Blot
Stripping BuVer (Pierce, Rockford, IL) at room temperature
for 30 min, then re-blocked, and re-probed with 1:5,000
dilution of -actin (Sigma Chemical Co.) to normalize for
equal protein loading for each sample.
Statistical calculation
The diVerence of RINs between “old” and “fresh” samples
was evaluated using the student t test. A p value <0.05
(p < 0.05) was considered as statistically signiWcant.
Results
PTEN splicing variants (SVs) are found in ‘aged’ blood 
from normal individuals but not in “fresh” blood 
from the same individuals
We initially drew blood from three healthy individuals.
RT-PCR and sequencing demonstrated that seven types of
SVs were found only in the “aged” blood samples, which
were kept at room temperature for 48 h before MNCs were
isolated, but were not found in their “fresh” blood counter-
parts. They included inclusions of portions of intron 3,
intron 5, intron 1, deletion of exon 6, partial deletion of
exon 8, and a complete deletion of exon 2–5. The intron
inclusions occurred either alone or combined with exon(s)
deletion (Fig. 1). There was no obvious connection indicat-
ing how the combinations would occur. In order to conWrm
this observation, we further collected peripheral blood from
additional 17 normal individuals. By using exon-speciWc
primers, we found these SVs are common in “aged” sam-
ples (Fig. 2). Four of the variants were previously reported
by other groups, including retention of a portion of intron 3
immediately adjoined to the 3’ of exon 3 (3b and 3c) alone;
inclusion of partial intron 5 (5c); and exon 6 skipping
(DelE6), respectively (Agrawal and Eng 2006; Sharrard
and Maitland 2000). No mutation was detected in the
related intron–exon Xanking region in genomic DNA in
either “fresh” or “aged” blood (data not shown). Since the
primers that were used in the Wrst run of PCR ampliWed the
full length of coding transcript of PTEN, we believe that
these SVs were not due to RNA degradation. By searching
the web site, http://www. fruitfly.org/sequence/human-
datasets.html, analysis of the sequences of intron-3 and
intron-5 retentions revealed that the inserted sequences
were related to the putatively alternative splicing sites
(scored as 0.23–0.97). This indicated that these SVs were
not mutation-related; instead, most likely, they were caused
by the relaxation of the splice Wdelity when the samples
were under stress.
Table 1 List of primers used in RT-PCR
Primer ID Sequence Location
1005F TCCTTTTTCTTCAGCCACAG 5UTR
2260R TTCATGGTGTTTTATCCCTCTT 3UTR
92439F GACAGCCATCATCAAAGAGA Exon 1
871R GATCACATAGACTTCCATTTTC Exon 8
225R TAAATTTGGCGGTGTCATAA Exon 4
324F TGACCAATGGCTAAGTGAAG Exon 4
501R CGCCTCTGACTGGGAATA Exon 6
674R GGTCCTGAATTGGAGGAAT Exon 7612 Hum Genet (2010) 128:609–614
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PTEN SVs are found in both “fresh” and “aged” 
EBV-transformed lymphoblastoid cell lines from healthy 
individuals but have no aVect on full-length PTEN protein 
expression
EBV-transformed lymphoblastoid cell lines are widely
used for mutation screening. In order to investigate whether
these SVs are present in EBV cell lines, we collected DNA
and RNA from both “fresh” and 48-h “aged” EBV cell lines
from six normal individuals. Although cells were treated
with puromycin before extraction of RNA and preparation
of cell lysates, SVs screening detected two types of SVs in
both “fresh” and “aged” EBV-transformed lymphoblastoid
cells from all six normal individual samples. They were
SV-3c and DelE6 (Fig. 3a). No mutation was found in their
DNA. The mechanism that causes alternative splicing in
EBV-transformed cells is unclear. However, western blot
data showed that the PTEN protein levels were not
decreased in EBV lymphoblasts (Fig. 3b). Our data indi-
cated that SVs can be detected in both “fresh” and “aged”
EBV cell lines, but they had no impact on PTEN protein
level.
RNA integrity analysis
In order to exclude that the aberrant splicing was the conse-
quence of RNA degradation, RNA of MNCs from 12 normal
individuals and EBV-transformed lymphoblastoid cell lines
from 6 healthy individuals were analyzed for RIN. The RINs
from “aged” blood were 7.5–9.0 (median 8.05), and signiW-
cantly diVerent from “fresh” blood (8.7–9.9, median 9.3,
p < 0.01) (Fig. 4a). Although this indicated that there was
RNA degradation in “old” blood, but the RINs from “aged”
EBV-transformed lymphoblastoid cells (8.8–10, median
9.8) had no signiWcant diVerence from that of the “fresh”
cells (8.9–10, median 10, p > 0.5) (Fig. 4b), and the SVs
were consistently found in both “fresh” and “aged” EBV-
transformed cells. This indicated that the SVs were not
associated with RNA degradation. In consideration that the
primers that were used in the nested PCR and the Wrst-run
Fig. 1 Schema. This schema 
represents the identiWed splicing 
variants in “aged” blood and 
EBV-transformed lymphoblasts 
from healthy individuals. Geno-
mic DNA sequence refers to 
Gene Bank/AF067844, mRNA 
refers to Gene Bank/U93051. 
The nomenclature used to 
describe the splice variants is 
according to the publication 
reported by Agrawal and Eng 
(2006). *Open yellow box 
indicates insertion sequence 
from intron
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Fig. 2 Aberrant splicing of PTEN observed in “aged” blood. RNAs
were extracted at the indicated time points. Genomic DNA was
removed from RNAs using the DNA-free™ kit before revere-tran-
scription. Primers for full length of PTEN-coding sequences are used
in the Wrst-run PCR, then a pair of exon-speciWc primers was used in
the second run PCR for each exon and Xanking region. NM normal
individual, WT wild type, SV splicing variant
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PCR for screening SVs would amplify only the full length of
PTEN-coding sequence, and the most of the aberrant tran-
scripts had intron retention, we are convinced that the
observed aberrant transcripts were not caused by RNA deg-
radation, instead, they were the consequence of relaxation of
the splice Wdelity when the samples were under stress.
Discussion
Somatic mutations that cause splicing deWcits rarely occur.
Germ-line sequence variations in both splice sites and regu-
latory elements have been implicated in susceptibility to
cancer (Kalnina et al. 2005). Analysis of the cancer-related
splicing-shifts suggests that many of these shifts act by
disrupting a tumor suppressor gene (Xu and Lee 2003).
However, some studies have demonstrated intriguing dis-
continuities between PTEN mutations and the subsequent
phenotypes. Sequencing of cDNA from patients and normal
individuals often reveals multiple SVs in PTEN, some of
which are non-mutation related (Agrawal and Eng 2006).
Agrawal and Eng (2006) reported that SVs, some of which
were identical to the ones we found, were naturally occur-
ring SVs in EBV cell lines, in patients with Cowden Syn-
drome, in sporadic breast cancer, and in a cDNA panel
comprising diVerent adult human tissues. They found
SV-3b and 3c were expressed inconsistently in normal
breast tissue and breast cancer tissues. They also demon-
strated that some of the SVs (SV-5c) had an impact on
cyclin D1 promoter activity. Interestingly, they found that
some of the SVs were regulated by over-expressed p53 in
the MCF7 cell line.
Since most of the tumor suppressors are related to cell
survival or death, it is rational to speculate that during the
process of blood aging, while cells are coping with stress,
many death-related mechanisms are initiated, which
includes protein degradation and splicing alterations. This
may cause the deregulation of protein and RNA, as well as
abnormal DNA damage repair, which eventually leads to
cell death or abnormal survival.
Illegitimate splicing is speciWcally referred to as the phe-
nomenon of splice alterations that are due to the relaxation
of the splice Wdelity and does not naturally occur. Typically
it is observed in aged samples, such as aged blood. It has
been reported in other tumor suppressor genes, such as
TSG101, FHIT, and NF1 by other groups (Gayther et al.
1997; Wimmer et al. 2000). It appears that this phenome-
Fig. 3 Aberrant splicing of PTEN observed in “fresh” and “aged”
EBV cell lines from normal individuals. a EBV lymphoblastoid cells
from normal individuals were treated by puromycin (150 g/ml) for
6 h before RNAs were extracted at the indicated time points. RT-PCR
followed the protocol as described for MNCs from peripheral blood.
b Normal PTEN protein expression in EBV cell lines with aberrant
splicing of PTEN. Cell lysates were prepared from unstimulated EBV
lymphoblastoid cells from normal individuals, which had been treated
with puromycin (150 g/ml) for 6 h before cell lysis. E-NM represents
EBV-transformed lymphoblasts from normal individual. WT wild
type, SV splicing variant
WT Exon III
WT Exon VI
WT Exon V
SV-3c
DelE6
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E-NM6
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E-NM5
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β-actin
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B
Fig. 4 Dot plots of RNA integrity number (RIN) from “fresh” and
“old” blood MNCs (a) and EBV lymphoblastoid cell Lines (b). The
bars indicate the median levels of each group614 Hum Genet (2010) 128:609–614
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non is related to the genes that are linked to the function of
cell survival. It is rational to speculate that illegitimate
splicing might be a mechanism that cells utilize to cope
with stress, which could function to either enhance or elimi-
nate the accumulation of damaged cells or tissues. Our data
indicates that the SVs of PTEN found in “aged” blood and
EBV cell lines were caused by illegitimate splicing, not a
pathological mechanism. Whether this mechanism applies
to other tissues needs to be further investigated.
Many RNAs are tissue- and developmental-stage-
speciWc. The awareness of the phenomenon of illegitimate
splicing is becoming more important, especially in the era
when RNA, and microRNA array studies are so popular. In
addition to preventing possible false information that may
be generated by ampliWcation of pseudogenes, our study
raises another issue that the age status of tissue should be
addressed when we analyze and interpret RNA-related data.
In conclusion, we have demonstrated that illegitimate
splicing occurs in the PTEN gene. This Wnding raises a
novel issue regarding the sample handling in studies related
to aberrant transcription. Published conclusions should be
made with caution when data was generated from non-fresh
samples, such as improperly preserved samples. When such
data are reported, the procedure regarding how the samples
and controls were handled should be addressed in detail.
Acknowledgments The authors would like to thank Dr. Ludwine M.
Messiaen for general assistance in experiment design, Dr. Hyoungsoo
Choi and Yuqing Liu for technical assistance, and Ms. Shelly Lensing
for helping preparing Fig. 4. This work was supported in part by US
Public Health Service grants R01 CA095621 and R01 HL082959
(P.D.E.) from the National Institutes of Health.
ConXict of interest The authors declare that they have no competing
interests.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Agrawal S, Eng C (2006) DiVerential expression of novel naturally
occurring splice variants of PTEN and their functional conse-
quences in Cowden syndrome and sporadic breast cancer. Hum
Mol Genet 15:777–787
Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple
control mechanisms and involvement in human disease. Trends
Genet 18:186–193
Carracedo A, PandolW PP (2008) The PTEN-PI3K pathway: of feed-
backs and cross-talks. Oncogene 27:5527–5541
Celebi JT, Wanner M, Ping XL, Zhang H, Peacocke M (2000) Associ-
ation of splicing defects in PTEN leading to exon skipping or
partial intron retention in Cowden syndrome. Hum Genet
107:234–238
Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T,
Wallin G, Parsons R, Longy M, Larsson C, Eng C (1997) Somatic
deletions and mutations in the Cowden disease gene, PTEN, in
sporadic thyroid tumors. Cancer Res 57:4710–4713
Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ,
Ritz J, Freedman A, Stiles C, Eng C (1999) PTEN is inversely
correlated with the cell survival factor Akt/PKB and is inactivated
via multiple mechanisms in haematological malignancies. Hum
Mol Genet 8:185–193
Gayther SA, Barski P, Batley SJ, Li L, de Foy KA, Cohen SN, Ponder
BA, Caldas C (1997) Aberrant splicing of the TSG101 and FHIT
genes occurs frequently in multiple malignancies and in normal
tissues and mimics alterations previously described in tumours.
Oncogene 15:2119–2126
Glick JL (1980) Fundamentals of human lymphoid cell culture,
pp 103–107
Kalnina Z, Zayakin P, Silina K, Line A (2005) Alterations of pre-
mRNA splicing in cancer. Genes Chromosomes Cancer 42:342–
357
Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C (2001)
Frequent loss of PTEN expression is linked to elevated phosphor-
ylated Akt levels, but not associated with p27 and cyclin D1
expression, in primary epithelial ovarian carcinomas. Am J Pathol
158:2097–2106
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call
KM, Tsou HC, Peacocke M, Eng C, Parsons R (1997) Germline
mutations of the PTEN gene in Cowden disease, an inherited
breast and thyroid cancer syndrome. Nat Genet 16:64–67
Liu YL, Castleberry RP, Emanuel PD (2009) PTEN deWciency is a
common defect in juvenile myelomonocytic leukemia. Leuk Res
33:671–677
Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z,
Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnet-
blanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A,
Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP,
Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C et al (1998)
Mutation spectrum and genotype-phenotype analyses in Cowden
disease and Bannayan–Zonana syndrome, two hamartoma syn-
dromes with germline PTEN mutation. Hum Mol Genet 7:507–
515
Sharrard RM, Maitland NJ (2000) Alternative splicing of the human
PTEN/MMAC1/TEP1 gene. Biochim Biophys Acta 1494:282–
285
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie
JM, Mao L, Khuri FR (2002) Lack of PTEN expression in non-
small cell lung cancer could be related to promoter methylation.
Clin Cancer Res 8:1178–1184
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons
R, Ellenson LH (1997) Mutations in PTEN are frequent in endo-
metrial carcinoma but rare in other common gynecological malig-
nancies. Cancer Res 57:3935–3940
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R
(1997) Somatic mutations of PTEN in glioblastoma multiforme.
Cancer Res 57:4183–4186
Wimmer K, Eckart M, Rehder H, Fonatsch C (2000) Illegitimate
splicing of the NF1 gene in healthy individuals mimics mutation-
induced splicing alterations in NF1 patients. Hum Genet
106:311–313
Xu Q, Lee C (2003) Discovery of novel splice forms and functional
analysis of cancer-speciWc alternative splicing in human
expressed sequences. Nucleic Acids Res 31:5635–5643
Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C,
Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, MatloV E,
Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C (2003)
Germline PTEN promoter mutations and deletions in Cowden/
Bannayan–Riley–Ruvalcaba syndrome result in aberrant PTEN
protein and dysregulation of the phosphoinositol-3-kinase/Akt
pathway. Am J Hum Genet 73:404–411